Found: 981
Select item for more details and to access through your institution.
Fournier's Gangrene and Sodium-Glucose Co-Transporter-2 Inhibitors: A Critical Combination in the Critical Care Unit.
- Published in:
- Journal of Critical & Intensive Care, 2024, v. 15, n. 2, p. 83, doi. 10.14744/dcybd.2024.4006
- By:
- Publication type:
- Article
Efficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta‐Analysis.
- Published in:
- Journal of Clinical Pharmacology, 2024, v. 64, n. 10, p. 1312, doi. 10.1002/jcph.2483
- By:
- Publication type:
- Article
The use of sodium–glucose co-transporter-2 inhibitors in heart failure: a practical overview.
- Published in:
- British Journal of Cardiac Nursing, 2024, v. 19, n. 9, p. 1, doi. 10.12968/bjca.2024.0013
- By:
- Publication type:
- Article
Effects of Co‐administration of Sulfonylureas and Antimicrobial Drugs on Hypoglycemia in Patients with Type 2 Diabetes Using a Case‐Crossover Design.
- Published in:
- Pharmacotherapy, 2020, v. 40, n. 9, p. 902, doi. 10.1002/phar.2450
- By:
- Publication type:
- Article
Pharmacokinetics, Safety, and Bioequivalence of Two Empagliflozin Formulations after Single Oral Administration under Fasting and Fed Conditions in Healthy Chinese Subjects: An Open‐label Randomized Single‐dose Two‐sequence, Two‐treatment, Two‐period Crossover Study
- Published in:
- Pharmacotherapy, 2020, v. 40, n. 7, p. 623, doi. 10.1002/phar.2432
- By:
- Publication type:
- Article
Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.
- Published in:
- Pharmacotherapy, 2017, v. 37, n. 4, p. 481, doi. 10.1002/phar.1903
- By:
- Publication type:
- Article
«SGLT2 INHIBITORS: RATIONALE FOR THE USE IN HEART FAILURE», RESOLUTION ON THE RESULTS OF THE PANEL OF EXPERTS WITH INTERNATIONAL PARTICIPATION, ALMATY.
- Published in:
- Interdisciplinary Approaches to Medicine, 2022, v. 3, n. 2, p. 38, doi. 10.26577/IAM.2022.v3.i2.08
- By:
- Publication type:
- Article
The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data.
- Published in:
- Northern Clinics of Istanbul, 2020, v. 7, n. 2, p. 167, doi. 10.14744/nci.2019.22697
- By:
- Publication type:
- Article
Inhibitory SGLT2 (3. část) - glukuronidace jako hlavní cesta biotransformace gliflozinů.
- Published in:
- Remedia, 2022, v. 32, n. 3, p. 312
- By:
- Publication type:
- Article
Empagliflozin v terapii srdečního selhání bez ohledu na ejekční frakci levé komory.
- Published in:
- Remedia, 2022, v. 32, n. 3, p. 285
- By:
- Publication type:
- Article
Studie EMPEROR-Preserved.
- Published in:
- Remedia, 2022, v. 32, n. 2, p. 139
- By:
- Publication type:
- Article
Green and white MEKC for determination of different anti-diabetic binary mixtures and their triple-combo pill.
- Published in:
- BMC Chemistry, 2023, v. 17, n. 1, p. 1, doi. 10.1186/s13065-023-00997-0
- By:
- Publication type:
- Article
HPLC-DAD technique for the quantification of a recently approved anti-diabetic triple combination along with two toxic official impurities: Toxicity confirmation aided by molecular docking application.
- Published in:
- BMC Chemistry, 2023, v. 17, n. 1, p. 1, doi. 10.1186/s13065-023-00927-0
- By:
- Publication type:
- Article
Oral semaglutide in kidney transplant recipients with metabolic syndrome: three Japanese cases.
- Published in:
- Renal Replacement Therapy, 2023, v. 9, n. 1, p. 1, doi. 10.1186/s41100-023-00492-1
- By:
- Publication type:
- Article
Two Japanese patients with stage G3b chronic kidney disease and impaired glucose metabolism after renal transplantation successfully treated with empagliflozin.
- Published in:
- Renal Replacement Therapy, 2020, v. 6, n. 1, p. N.PAG, doi. 10.1186/s41100-020-00303-x
- By:
- Publication type:
- Article
Apelin and Copeptin Levels in Patients With Chronic SIAD Treated With Empagliflozin.
- Published in:
- Journal of the Endocrine Society, 2024, v. 8, n. 7, p. 1, doi. 10.1210/jendso/bvae106
- By:
- Publication type:
- Article
Prevalence of Admission Hyponatremia in Patients With Diabetes Treated With and Without an SGLT2 inhibitor.
- Published in:
- Journal of the Endocrine Society, 2023, v. 7, n. 4, p. 1, doi. 10.1210/jendso/bvad011
- By:
- Publication type:
- Article
A32 EMPAGLIFOZIN IMPROVES GASTROINTESTINAL INFLAMMATION IN A MOUSE MODEL OF COLITIS.
- Published in:
- Journal of the Canadian Association of Gastroenterology, 2021, v. 4, p. 213, doi. 10.1093/jcag/gwab002.031
- By:
- Publication type:
- Article
Renoprotective effects of empagliflozin in type 1 and type 2 models of diabetic nephropathy superimposed with hypertension.
- Published in:
- GeroScience, 2022, v. 44, n. 6, p. 2845, doi. 10.1007/s11357-022-00610-7
- By:
- Publication type:
- Article
SGLT2 inhibitors: Indications, doses and licences in adults.
- Published in:
- Diabetes & Primary Care, 2023, v. 25, n. 1, p. 9
- Publication type:
- Article
SGLT2 inhibitors: Indications, doses and licences (England, Scotland and Wales).
- Published in:
- Diabetes & Primary Care, 2021, v. 23, n. 6, p. 175
- Publication type:
- Article
Comparison of Renal and Metabolic Effects of Empagliflozin and Dapagliflozin on Type 2 Diabetes-Induced Rats.
- Published in:
- 2022
- By:
- Publication type:
- Abstract
Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome.
- Published in:
- eLife, 2023, p. 1, doi. 10.7554/eLife.83353
- By:
- Publication type:
- Article
EMMY: The continued expansion of clinical applications of SGLT2 inhibitors.
- Published in:
- Global Cardiology Science & Practice, 2023, v. 2023, n. 1, p. 1, doi. 10.21542/gcsp.2023.5
- By:
- Publication type:
- Article
EMPEROR-Preserved: SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction.
- Published in:
- Global Cardiology Science & Practice, 2021, v. 2021, n. 3, p. 1, doi. 10.21542/gcsp.2021.17
- By:
- Publication type:
- Article
Cardiac Late Sodium Channel Current (Late-I<sub>Na</sub>) is a Molecular Target in the Heart for the Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitor Empagliflozin, Contributing to Cardioprotection.
- Published in:
- Rhythmos, 2021, v. 16, n. 3, p. 68
- By:
- Publication type:
- Article
EMPA-TROPISM: Empagliflozin in Nondiabetic HFrEF Patients Significantly Improves LV Volumes, LV Mass, LV Systolic Function, Functional Capacity, and Quality of Life When Compared With Placebo.
- Published in:
- Rhythmos, 2021, v. 16, n. 2, p. 43
- By:
- Publication type:
- Article
EMPA-REG Outcome Trial: Hypoglycemia Increases Risk of HF Hospitalization (HFH) and MI/Hypoglycemia Risk was not Increased with Empagliflozin and Incident Hypoglycemia did not Attenuate its Cardio-Protective Effects.
- Published in:
- Rhythmos, 2020, v. 15, n. 2, p. 39
- By:
- Publication type:
- Article
EMPA-REG OUTCOME Trial: Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 41
- By:
- Publication type:
- Article
ODYSSEY Outcomes: The Price of Alirocumab Would Have to be Reduced Drastically to be Cost-Effective.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 40
- By:
- Publication type:
- Article
Impact of baseline ECG characteristics on changes in cardiac biomarkers and echocardiographic metrices after acute myocardial infarction treated with Empagliflozin.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-64175-5
- By:
- Publication type:
- Article
Effects of empagliflozin on reproductive system in men without diabetes.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-64684-3
- By:
- Publication type:
- Article
Association of anti-diabetic drugs and COVID-19 outcomes in patients with diabetes mellitus type 2 and cardiomyopathy.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-57871-9
- By:
- Publication type:
- Article
Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes.
- Published in:
- Journal of Personalized Medicine, 2023, v. 13, n. 5, p. 747, doi. 10.3390/jpm13050747
- By:
- Publication type:
- Article
SGLT2 inhibitors and finerenone in non-diabetic CKD: a step into the (near) future?
- Published in:
- Clinical Kidney Journal, 2024, v. 17, n. 1, p. 1, doi. 10.1093/ckj/sfad272
- By:
- Publication type:
- Article
EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors.
- Published in:
- Clinical Kidney Journal, 2023, v. 16, n. 8, p. 1187, doi. 10.1093/ckj/sfad082
- By:
- Publication type:
- Article
Sodium–glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria.
- Published in:
- Clinical Kidney Journal, 2021, v. 14, n. 12, p. 2463, doi. 10.1093/ckj/sfab096
- By:
- Publication type:
- Article
Acute interstitial nephritis due to sodium-glucose co-transporter 2 inhibitor empagliflozin.
- Published in:
- Clinical Kidney Journal, 2021, v. 14, n. 3, p. 1020, doi. 10.1093/ckj/sfaa033
- By:
- Publication type:
- Article
Mechanism and reversal of drug-induced nephrotoxicity on a chip.
- Published in:
- Science Translational Medicine, 2021, v. 13, n. 582, p. 1, doi. 10.1126/scitranslmed.abd6299
- By:
- Publication type:
- Article
Use of a Sodium-Glucose Cotransporter 2 Inhibitor, Empagliflozin, in a Patient with Rabson-Mendenhall Syndrome.
- Published in:
- Hormone Research in Paediatrics, 2021, v. 94, n. 7/8, p. 313, doi. 10.1159/000519613
- By:
- Publication type:
- Article
Interview with Dr. Michael McDonald on Empagliflozin.
- Published in:
- University of Toronto Medical Journal, 2022, v. 99, n. 1, p. 51
- By:
- Publication type:
- Article
Type Disparity in Sodium–Glucose Cotransporter-2 Inhibitors in Incidences of Renal Cell Carcinoma: A Propensity-Score-Matched Cohort Study.
- Published in:
- Cancers, 2024, v. 16, n. 11, p. 2145, doi. 10.3390/cancers16112145
- By:
- Publication type:
- Article
Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY 3-36 , and Empagliflozin on Early MASLD in Diet-Induced Obese Rats.
- Published in:
- Nutrients, 2024, v. 16, n. 6, p. 904, doi. 10.3390/nu16060904
- By:
- Publication type:
- Article
Formulation and Evaluation of Empagliflozin drug loaded Polymeric Nanoparticles for the Treatment of type 2 Diabetes Mellitus (T2DM).
- Published in:
- Current Trends in Biotechnology & Pharmacy, 2022, v. 16, n. 3, p. 308, doi. 10.5530/ctbp.2022.3.44
- By:
- Publication type:
- Article
Empagliflozin Reduces BP in Hypertensive Type 2 Diabetics.
- Published in:
- MD Conference Express, 2014, v. 14, n. 20, p. 14, doi. 10.1177/155989771420008
- By:
- Publication type:
- Article
Reductions in HbA1c and Weight in Type 2 Diabetics with the Empagliflozin Add-On Regimen.
- Published in:
- MD Conference Express, 2014, v. 14, n. 20, p. 15, doi. 10.1177/155989771420009
- By:
- Publication type:
- Article
The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome.
- Published in:
- PLoS ONE, 2017, v. 12, n. 10, p. 1, doi. 10.1371/journal.pone.0186910
- By:
- Publication type:
- Article
Population Pharmacokinetic– Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
- Published in:
- Journal of Clinical Pharmacology, 2018, v. 58, n. 5, p. 640, doi. 10.1002/jcph.1051
- By:
- Publication type:
- Article
RP-HPLC METHOD DEVELOPMENT FOR SIMULTANEOUS ESTIMATION OF EMPAGLIFLOZIN, PIOGLITAZONE, AND METFORMIN IN BULK AND TABLET DOSAGE FORMS.
- Published in:
- Acta Poloniae Pharmaceutica, 2021, v. 78, n. 3, p. 305, doi. 10.32383/appdr/139635
- By:
- Publication type:
- Article
Empagliflozin to prevent post‐operative atrial fibrillation in patients undergoing coronary artery bypass graft surgery: Rationale and design of the EMPOAF trial.
- Published in:
- Pacing & Clinical Electrophysiology, 2024, v. 47, n. 8, p. 1087, doi. 10.1111/pace.15038
- By:
- Publication type:
- Article